BioCentury | Oct 31, 2020
Translation in Brief

A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx

...KSQ plans to submit an IND for KSQ-4279 next year. AstraZeneca plc (LSE:AZN; NASDAQ:AZN) markets the PARP inhibitor.SynDevRx...
...1 Danielle Golovin BDTX-189 Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) SDX-7320 The Scripps Research Institute Nanjing University Heidelberg University Black Diamond Therapeutics Inc. KSQ Therapeutics Inc. SynDevRx Inc. Ubiquitin...
BioCentury | Dec 14, 2015
Product Development

Risk-benefit litmus test

...how beloranib may relate to thrombosis in Prader-Willi. James Shanahan, VP of business development at SynDevRx Inc....
...said so far there's no hypothesis for why MetAP2 inhibition would cause or aggravate thrombosis. SynDevRx's...
...Pasadena, Calif. Harvard Medical School, Boston, Mass. National Organization for Rare Diseases (NORD), Danbury, Conn. SynDevRx Inc....
BioCentury | Apr 27, 2009
Clinical News

Mersana preclinical data

...free XMT-1191. Data were presented at the American Association for Cancer Research meeting in Denver. SynDevRx Inc....
BioCentury | Jul 17, 2008
Distillery Therapeutics

This Week in Therapeutics

...to N-(2-hydroxypropyl)methacrylamide (HPLA), is in preclinical development by SynDevRx Inc. to treat cancer. Patent application filed; SynDevRx...
BioCentury | Jan 14, 2008
Company News

SynDevRx Inc. scientific advisory board update

SynDevRx Inc. , Cambridge, Mass. Business: Cancer Appointed: Bruce Zetter, CSO of Children's Hospital Boston and VP of research at Harvard Medical School, as chairman; Rakesh Jain, professor of tumor biology at Massachusetts General Hospital and...
Items per page:
1 - 5 of 5
BioCentury | Oct 31, 2020
Translation in Brief

A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx

...KSQ plans to submit an IND for KSQ-4279 next year. AstraZeneca plc (LSE:AZN; NASDAQ:AZN) markets the PARP inhibitor.SynDevRx...
...1 Danielle Golovin BDTX-189 Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) SDX-7320 The Scripps Research Institute Nanjing University Heidelberg University Black Diamond Therapeutics Inc. KSQ Therapeutics Inc. SynDevRx Inc. Ubiquitin...
BioCentury | Dec 14, 2015
Product Development

Risk-benefit litmus test

...how beloranib may relate to thrombosis in Prader-Willi. James Shanahan, VP of business development at SynDevRx Inc....
...said so far there's no hypothesis for why MetAP2 inhibition would cause or aggravate thrombosis. SynDevRx's...
...Pasadena, Calif. Harvard Medical School, Boston, Mass. National Organization for Rare Diseases (NORD), Danbury, Conn. SynDevRx Inc....
BioCentury | Apr 27, 2009
Clinical News

Mersana preclinical data

...free XMT-1191. Data were presented at the American Association for Cancer Research meeting in Denver. SynDevRx Inc....
BioCentury | Jul 17, 2008
Distillery Therapeutics

This Week in Therapeutics

...to N-(2-hydroxypropyl)methacrylamide (HPLA), is in preclinical development by SynDevRx Inc. to treat cancer. Patent application filed; SynDevRx...
BioCentury | Jan 14, 2008
Company News

SynDevRx Inc. scientific advisory board update

SynDevRx Inc. , Cambridge, Mass. Business: Cancer Appointed: Bruce Zetter, CSO of Children's Hospital Boston and VP of research at Harvard Medical School, as chairman; Rakesh Jain, professor of tumor biology at Massachusetts General Hospital and...
Items per page:
1 - 5 of 5